Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
63
Frequently Asked Questions
What is Market Cap of Akero Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Akero Therapeutics Inc market cap is $3.52B.
What is the 52-week high for Akero Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Akero Therapeutics Inc 52 week high is $58.40 as of September 06, 2025.
What is the 52-week low for Akero Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Akero Therapeutics Inc 52 week low is $21.34 as of September 06, 2025.
What is Akero Therapeutics Inc stock price today?
Akero Therapeutics Inc stock price today is $44.72.
What was Akero Therapeutics Inc stock price yesterday?
Akero Therapeutics Inc stock price yesterday was $44.03.
What is the PE ratio of Akero Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Akero Therapeutics Inc’s P/E ratio is -11.58.
What is the Price-to-Book ratio of Akero Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Akero Therapeutics Inc P/B ratio is 3.4303.
What is the 50-day moving average of Akero Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Akero Therapeutics Inc 50-day moving average is $50.09.
How many employess does Akero Therapeutics Inc has?